الصفحة الرئيسية>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>E3 Ligase Ligand-Linker Conjugates 20

E3 Ligase Ligand-Linker Conjugates 20 (Synonyms: Cereblon Ligand-Linker Conjugates 2; E3 Ligase Ligand-Linker Conjugates 20)

رقم الكتالوجGC33390

يمكن استخدام E3 Ligase Ligand-Linker Conjugates 20 (Cereblon Ligand-Linker Conjugates 2) ، وهو اتحاد مركب E3 ligase ligand-linker الذي يشتمل على ترابط cereblon القائم على ثاليدوميد ورابط ، في توليف PROTACs.

Products are for research use only. Not for human use. We do not sell to patients.

E3 Ligase Ligand-Linker Conjugates 20 التركيب الكيميائي

Cas No.: 1950635-15-0

الحجم السعر المخزون الكميّة
100mg
321٫00
متوفر
500mg
1241٫00
متوفر
1g
2298٫00
متوفر
2g
3218٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

E3 Ligase Ligand-Linker Conjugates 20 is a degron-linker (refer to Compound DL7-TL). The PROTAC linker is bound lo at least one targeting ligand.

Degron-linker-targeting ligand, wherein the linker is covalently bound lo at least one degron and at least one targeting ligand, the degron is a compound capable of binding to an ubiquitin ligase such as an E3 ubiquitin ligase (e g, cereblon), and the targeting ligand is capable of binding to the targeted protein (s)[1].

[1]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

مراجعات

Review for E3 Ligase Ligand-Linker Conjugates 20

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for E3 Ligase Ligand-Linker Conjugates 20

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.